Skip to content

The efficacy of D-Cycloserine and psychotherapy on symptoms improvement in the adults with anxiety

The efficacy of augment of D-Cycloserine and cognitive-behavioral therapy on symptoms improvement in the adolescents with one type of anxiety disorders: A double-blind randomized controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012071610297N1
Enrollment
36
Registered
2013-08-21
Start date
2011-09-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders. Anxiety disorder, unspecified

Interventions

Intervention 1: Case group received a 50-mg D-cycloserine capsule (made in pharmacology school of Isfahan University of Medical Sciences) daily for a month in addition to the psychotherapy. Intervent
Treatment - Drugs
Case group received a 50-mg D-cycloserine capsule (made in pharmacology school of Isfahan University of Medical Sciences) daily for a month in addition to the psychotherapy.
Control group, received Placebo (made in pharmacology school of Isfahan University of Medical Sciences) daily for a month in addition to the sychotherapy.

Sponsors

Isfahan University of Medical Sciences, School of Medicine, Vice Chancellor for Research
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 20 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- The adolescents with the age of 12-20 years with anxiety disorders needing therapeutic interventions and receiving anti-anxiety treatment according to the children psychiatrist, 2- Lack of any background pertaining to serious psychological or physical problems, mood disorders, psychosis or delusional disorders and drug dependency,3- Lack of any changes in anti-anxiety drugs or any changes in their doses during 4 weeks before the study,4- Lack of learning disorders based on mental check-up,5- lack of any background associated with seizure and severe depression coupled with the thoughts of suicide, 6- The IQ equal or higher than 80 (it was measured applying Raven Test and by an independent psychiatrist) are of inclusion criteria. Exclusion Criteria: 1-The patients who were absent for more than one session and those whose parents or themselves did not intend to continue the treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Improvement of the anxiety disorders symptoms. Timepoint: One month after the beginning of the medication and psychotherapy. Method of measurement: “SCARED” score.

Secondary

MeasureTime frame
Children's Automatic Thoughts Scale Score. Timepoint: Three months post treatment. Method of measurement: CATS questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Soheilimehr

Department of Psychiatry, Isfahan University of Medical Sciences

alisoheilimehr@yahoo.com, soroorarman@yahoo.com+98 31 1792 3011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026